Clinical breast cancer
Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis.
Lingling Ye, Yan Dai, Liushan Chen, Yuqi Liang, Jiafa He, Shenying Chen, Xue Song, Rui Xu, Qianjun Chen
Published: 202510.1016/j.clbc.2025.10.018
Abstract
CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line and second-line therapy for advanced HR+/HER2- breast cancer. This study aimed to evaluate the impact of HER2 low expression on the efficacy of breast cancer patien…
Preview only. Read the full abstract at the source